Does semaglutide actually cause 'Ozempic face'? Here's the data

What did @user6760823034903 actually say?

The creator argues that celebrity photos prove GLP-1 drugs like Ozempic cause dramatic, alarming physical changes, describing results as "completely off" and expressing grief over what she sees. She also shares a personal account of body dysmorphia during a difficult period in her life, then pivots to criticizing drug commercials featuring Serena Williams and Charles Barkley. The core claim is that visible facial and body changes in celebrities constitute proof of dangerous side effects.

She distinguishes between weight loss in people with obesity, which she frames as acceptable, and weight loss in people who were already at a healthy weight, calling the latter "drastic" and troubling. She implies that the drug is being normalized through advertising despite clear visible harms. The framing leans heavily on photos and appearance as clinical evidence, which is where the argument starts to fall apart.

Does the science back this up?

Not really, at least not in the way she presents it. "Ozempic face" is a real phenomenon with a real mechanism, but photos of celebrities are not clinical evidence of harm, and the creator conflates aesthetic change with medical danger.

Rapid weight loss of any kind, whether from surgery, caloric restriction, or GLP-1 receptor agonists, causes loss of facial adipose tissue. This produces hollowing around the cheeks, eyes, and temples. Dermatologists have documented this clinically, and it is not unique to semaglutide. A 2023 commentary in Facial Plastic Surgery and Aesthetic Medicine by Hartman et al. noted that the facial aging effect is proportional to the rate and magnitude of weight loss, not the drug mechanism specifically. The face changes because fat pads shrink. That is physiology, not toxicity.

What the creator describes as proof of "worst fears" side effects is largely a cosmetic consequence of significant weight loss, which is the intended outcome of the drug. Serious adverse events from semaglutide, including pancreatitis, thyroid C-cell concerns, and gastrointestinal complications, are documented in clinical literature but are not visible in photographs.

What did they get wrong (or right)?

She got a few things partially right. Her observation that these drugs are being heavily normalized through celebrity advertising while risks remain underexplained to the public is a legitimate concern. Researchers and bioethicists have written about the gap between how GLP-1 drugs are marketed and how informed patients actually are about long-term unknowns. That critique has merit.

Her personal disclosure about body dysmorphia is also genuinely thoughtful and shows some self-awareness about how perception distorts reality, which ironically applies to her own reading of celebrity photos.

Where she goes wrong is in treating paparazzi photos as diagnostic data. Saying a celebrity's appearance is "completely off" is not a fact-check of a drug. It is aesthetic judgment. She also conflates correlation with causation. A celebrity who looks gaunt after reported Ozempic use may have other contributing factors, including diet, stress, illness, or other medications. She does not acknowledge this, and that is a meaningful gap. Framing appearance changes as proof of dangerous side effects without clinical sourcing is the kind of reasoning that spreads medical misinformation, even when it comes from a place of genuine concern.

What should you actually know?

GLP-1 receptor agonists do cause real, documented side effects, and patients deserve accurate information about all of them, including the ones that are less visible than facial volume loss.

• Facial fat loss during rapid weight loss is physiological and not exclusive to GLP-1 drugs. It happens with any significant caloric deficit.
• Documented serious risks from semaglutide include nausea, vomiting, gastroparesis-like symptoms, and a boxed warning about thyroid C-cell tumors based on rodent studies. These are not visible in photos.
• A 2021 trial published in the New England Journal of Medicine (Wilding et al.) showed semaglutide produced an average 15 percent body weight reduction. Facial changes at that magnitude of loss are expected regardless of mechanism.
• The FDA has not approved semaglutide or tirzepatide for use in people without obesity or type 2 diabetes, and off-label cosmetic or weight-optimization use in already-lean individuals carries risk profiles that are not well-studied.
• If someone is using these drugs without a BMI or metabolic indication, that is a legitimate concern worth raising. But the evidence should be clinical, not photographic.

Bottom line on the advertising criticism

The creator's frustration with ubiquitous GLP-1 advertising is understandable and echoes concerns raised by medical ethicists. Direct-to-consumer pharmaceutical advertising in the United States has long been criticized for overstating benefits and minimizing risks. A 2021 analysis in JAMA Internal Medicine by Schwartz and Woloshin documented systematic imbalance in how drug ads present risk information. That concern applies here. But outrage at celebrity photos is not the same as a rigorous critique of drug marketing, and conflating the two weakens an argument that could otherwise be worth making.